A multinational research team has published the protocol for a two-year study comparing recreational and medicinal cannabis users across six countries, using real-time mobile phone sampling to track mood, cognition, and mental health. This is a design paper only, with no results yet available, but its cross-cultural scope and balanced framing of both harms and benefits represent a meaningful step forward for cannabis research methodology.

Clinicians managing patients who use cannabis for symptom relief face a persistent knowledge gap: the evidence base has been shaped by funding structures that favor either harm-focused or benefit-focused research, and nearly all prior longitudinal work has been conducted within single countries with limited legal variation. Medicinal users, who may differ substantially from recreational users in age, comorbidity, and use patterns, have rarely been studied alongside them in the same design. A well-executed multinational study comparing these populations across jurisdictions could eventually provide the kind of contextual, balanced evidence that clinical decision-making urgently requires.

Cannabis use for both recreational and medicinal purposes continues to expand globally, yet the evidence base guiding clinicians remains fragmented. Research on cannabis and mental health has been conducted largely within single countries, siloed into either harm-focused or benefit-focused paradigms, and almost entirely neglecting direct comparisons between medicinal and recreational user populations. The Blowing Minds study protocol, coordinated from Erasmus University Rotterdam, describes a fully online longitudinal investigation targeting 1,800 cannabis users across the Netherlands, the United States, Brazil, and Canada. Its rationale rests on two well-supported observations: that real-time Experience Sampling Method (ESM) data dramatically reduce recall bias compared to traditional surveys, and that cultural and legal context may meaningfully moderate how cannabis affects mental health, cognition, and patterns of problematic use.

No empirical results are reported in this publication. The protocol describes a 14-day intensive ESM phase with multiple daily mobile assessments, followed by structured cognitive and mental health evaluations at baseline, one year, and two years. Key planned outcomes include positive and negative affect, craving, sleep quality, mental health symptom trajectories, and cannabis use disorder criteria. The authors hypothesize that medicinal users may meet physical but not psychological CUD criteria, though they acknowledge this remains genuinely uncertain. They identify online recruitment and self-reported cannabis potency as limitations and state their intent to pursue a data-driven analytic approach. Results are anticipated no earlier than 2027, and the team plans an open-access database for future replication.

Before the Data: Inside the Protocol for One of Cannabis Research’s Most Ambitious Studies

Every day, clinicians are asked whether cannabis is helping or harming their patients, and for most of those questions, the honest answer is still “we don’t have good data.” A new multinational research protocol is trying to change that. But it hasn’t generated results yet, and understanding what it’s designed to do, and where it might fall short, is itself scientifically important. The Blowing Minds protocol paper does not claim to have discovered anything about cannabis. What it offers instead is a blueprint, and a genuinely thoughtful one. The authors correctly identify that cannabis research has been pulled in opposite directions by funding structures: public agencies tend to fund harm-focused studies, while industry sponsors favor benefit-focused work. The result is a literature that is polarized rather than balanced, with medicinal users almost entirely absent from longitudinal designs that compare them directly with recreational users. The decision to use Experience Sampling Method, in which participants report their mood and behavior multiple times per day via mobile phone rather than recalling it weeks later, is a meaningful improvement. Asking someone to rate their mood every few hours gives a very different picture than asking them to remember how they felt all week at a single end-of-week interview. That difference matters clinically, because the acute and sustained effects of cannabis on affect, craving, and sleep are precisely the dynamics most distorted by retrospective recall.

The most distinctive design element is the cross-jurisdictional comparison. By sampling users from countries where cannabis is illegal, decriminalized, and fully legal, the protocol is positioned to ask whether policy context itself shapes health outcomes, not just access. This is directly relevant to legislators and regulators, not only to clinicians. However, the protocol’s most significant vulnerability lies in exactly this strength. Online social media recruitment across vastly different cultural and legal contexts is likely to produce highly non-representative samples. Comparing health outcomes across cities by only surveying people who respond to billboard advertisements would give you data, but you would not know how much it represents everyone. Similarly, comparing a Dutch sample recruited through Instagram with a Brazilian sample recruited through a different platform creates unmeasured confounders that may be impossible to disentangle from genuine cross-cultural differences. The reliance on self-reported cannabis potency, without any product testing, further compounds this problem. Studying the health effects of a substance while only asking participants to estimate its active ingredient content is a recognized limitation in alcohol research, and it applies with equal force here, particularly across countries with very different product markets.

What I would tell a patient is straightforward: we are still in early days of understanding how cannabis affects different people long-term, especially those using it medicinally on their own, and this study is trying to get better answers, but they are not in yet. What I would tell a colleague is that the design is credible and the gaps it targets are real, but citing this as evidence of anything would be premature. And what I would tell a policymaker is that cannabis policy is currently running ahead of the evidence, and this study’s cross-jurisdictional design is its most policy-relevant feature, though results will take years and will require rigorous measurement equivalence testing across cultures to be interpretable. A protocol paper defines what a study will attempt to learn and what assumptions it embeds. Reading it critically before results arrive is how we prevent post-hoc rationalization of design choices and hold researchers accountable to their stated intentions.

For clinicians, this protocol occupies an unusual but important position in the research arc: it is a pre-results publication that nonetheless has practical value. The detailed enumeration of what has and has not been studied in medicinal cannabis users provides a useful reference for practitioners who need to explain to patients why the evidence base for their self-directed cannabis use remains thin. The planned head-to-head comparison of medicinal and recreational users across legal contexts is precisely the kind of design that could, if results are eventually published, move clinical conversations from anecdote to data.

From a pharmacological perspective, the protocol’s attention to product type, THC and CBD content, and route of administration reflects an awareness that “cannabis” is not a single intervention but a heterogeneous family of exposures. However, without analytical verification of product composition, the pharmacological precision of the data will be limited. Clinicians should note that the protocol does not include any intervention arm, placebo comparison, or physician-supervised dosing. This means that even eventual positive findings will reflect associations within naturalistic use patterns, not evidence for therapeutic efficacy. The most actionable recommendation for now is to monitor for the study’s results, expected at 2027 or later, and to treat any interim citations of this protocol as methodological, not clinical, evidence.

This is a study protocol paper published in a peer-reviewed psychiatry journal. It contains no original empirical data and occupies a position below even observational studies in the evidence hierarchy, functioning instead as a methodological and conceptual contribution. The single most important inference constraint is absolute: no claims about cannabis effects on any outcome can be drawn from this document because no data have been collected, analyzed, or reported.

Prior ESM studies of cannabis and affect, including work by Denson and colleagues, have generally found that negative affect increases before cannabis use in frequent users and decreases afterward, while findings for positive affect have been inconsistent and appear to differ by cannabis use disorder severity. Cross-sectional surveys comparing medicinal and recreational users have identified demographic and clinical differences but have not tracked outcomes longitudinally. The Blowing Minds protocol extends this literature by proposing to combine ESM with long-term cognitive and mental health follow-up across multiple legal contexts, an approach that no prior study has executed at this scale. Work from the authors’ own lab has previously suggested that local legislation may not reliably predict perceived cannabis harms or benefits, a finding the new study is designed to investigate more rigorously.

Because no data have been analyzed, this question applies prospectively rather than retrospectively. The most consequential analytic choice will be how the team handles cross-cultural measurement equivalence. If the same ESM questionnaires are used across languages and cultural contexts without formal testing of whether items measure the same constructs equivalently, apparent cross-national differences in cannabis effects could reflect measurement artifacts rather than genuine moderator effects. A reasonable alternative would be to require demonstrated metric invariance across sites before pooling data for cross-cultural comparisons. Additionally, the threshold for categorizing dual-motive users (60% of reported use occasions) is a pragmatic cutoff that, if set differently, could shift group composition and alter the medicinal-vs-recreational comparison meaningfully.

The most consequential misreading would be treating the hypotheses stated in this protocol as established findings. The authors offer informed predictions, such as the suggestion that medicinal users may meet physical but not psychological CUD criteria, but these are explicitly provisional and drawn from a mixed literature. Neither the narrative literature review embedded in this protocol nor the planned open-access database should be confused with existing empirical resources. Readers should also resist the temptation to assume that because the protocol assesses both harms and benefits, the current evidence for each is symmetrical. It is not; the balance of existing research varies considerably by outcome domain.

The Blowing Minds protocol provides a detailed and well-reasoned methodological blueprint for a cross-cultural longitudinal cannabis study that addresses genuine gaps in current research. It does not establish any empirical finding about cannabis effects on mental health, cognition, or sleep. Its value today lies in its design innovations and its articulation of where the field’s evidence is weakest. Clinicians should track this study’s results but cannot draw any practice-changing conclusions from the protocol alone.

Does this study prove that cannabis is safe or effective for mental health?

No. This is a protocol paper describing how researchers plan to study cannabis use. No data have been collected or analyzed, and no conclusions about safety or efficacy can be drawn from it. Results are expected no earlier than 2027.

What is the Experience Sampling Method (ESM) and why does it matter?

ESM involves participants reporting their mood, behavior, and cannabis use multiple times per day on their mobile phones, in real time rather than from memory weeks later. This approach reduces recall bias and captures the moment-to-moment dynamics of how cannabis use relates to mood and craving, which traditional surveys cannot do.

Should I change my cannabis use based on this paper?

No. Because there are no results from this study yet, it provides no basis for changing any clinical or personal cannabis decisions. If you are using cannabis medicinally, discuss your use with a healthcare provider who can help you evaluate the best available evidence for your specific situation.

Why is this protocol worth paying attention to if there are no results?

Protocol papers establish the rules of a study before results come in, much like a blueprint establishes the plan for a building before construction begins. Reading protocols critically allows clinicians and the public to evaluate whether the study’s eventual conclusions are supported by its design, and helps hold researchers accountable to their stated methods.

Have thoughts on this? Share it: